PerspectiveInfectious Disease

A sustainable model for antibiotics

See allHide authors and affiliations

Science  06 Mar 2015:
Vol. 347, Issue 6226, pp. 1062-1064
DOI: 10.1126/science.aaa3048

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Despite the alarming increase in the prevalence of drug-resistant bacterial infections, far fewer new antibiotics have been approved in the past decade than at the peak in the 1980s (1). The situation is particularly alarming for serious infections by Gram-negative bacteria, some of which are becoming untreatable by modern antibiotics (24). Particularly in low- and middle-income countries, untreatable infections are becoming an everyday reality in hospital and care settings (5). Increasing recognition of this problem is spurring a number of public and private initiatives on both sides of the Atlantic (68). To more effectively counter the threat of emerging resistance, we must increase the number of innovative new antibiotics in development and harness advances in diagnostic technology to preserve their efficacy.